Genmab — Maj 2015
-
Men syntes ikke data er særlig gode. PFS ca. 19 måneder for ELD mod 14 for LD alene
-
men stadig meget høj hasard ratio for Elotuzumab både med revlimid og i velcade studiet. Jeg er ikke omponeret af Elo
-
Elo med velcade: http://abstracts.asco.org/156/AbstView_156_144027.html ikke det vilde heller
-
Only 1 pt (MOR202 0.15 mg/kg q2w) generated a transient anti-drug antibody response to MOR202.
-
-
http://abstracts.asco.org/156/AbstView_156_151048.html Arzerra Idelalisib med pæn forøgelse af effekt med idelalisib.
-
Dog alligevel MTD nået for HTF: Der vil blive inkluderet data fra flere patienter i posteren, når den præsenteres, herunder observerede dosisbegrænsende toksiciteter i patientkohorten, der fik 2,2 mg/kg
-
Dog fint der er nogle responser. Det er meget early data, lad os se til mig.
-
Maj
-
Det mest positive er at Elotuzumab og MOR202 data er dårlige efter min mening, Dara bliver klart stjernen indenfor MM
-
Men del 2 af studiet udvides fra 30 til 80 patienter så de går da i hvert fald videre Genmab, så de er tilfredse
-
33 daratumumab patient samples (from single-agent or combination studies) were DIRA tested and clinical responses assessed; 13 (39%) had no M-protein (DIRA -ve) and 10 were confirmed as CR. 20 patients had malignant M-protein remaining (DIRA +ve) and monitoring
-
-
Arzerra ser underligt ud. Vildt god PFS og ORR og så er der nærmest ingen forskel i OS, men det skyldes vel blot at median OS ikke er nået eller hvad ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind